MAJOR RESPONSIBILITIES
FORMAL KNOWLEDGE
SPECIALIZED TRAINING OR KNOWLEDGE
COMPETENCIES/SKILLS
SPECIAL MENTAL OR PHYSICAL DEMANDS
The salary for this role is $44,000. The final candidate's relevant experience/skills will be considered before an offer is extended. Actual starting pay will vary based on non-discriminatory factors including, but not limited to, geographic location, experience, skills, specialty, and education.
ACS provides staff a generous paid time off policy; medical, dental, retirement benefits, wellness programs, and professional development programs to enhance staff skills. Further details on our benefits can be found on our careers site at: jobs.cancer.org/benefits. We are a proud equal opportunity employer.
","datePosted":"2025-04-07T07:28","employmentType":"FULL_TIME","jobLocation":[{"@type":"Place","address":{"@type":"PostalAddress","addressLocality":"Salt Lake City, UT, USA","addressRegion":null,"addressCountry":"United States"}}],"directApply":false,"hiringOrganization":{"@type":"Organization","name":"American Cancer Society","sameAs":"https://cancer.org/","logo":"https://storage.googleapis.com/simplify-imgs/companies/3d8fe5c2-8174-43e7-8f9f-efe06f2ef94a/logo.png"},"baseSalary":{"@type":"MonetaryAmount","currency":"USD","value":{"@type":"QuantitativeValue","minValue":44000,"maxValue":44000,"unitText":"YEAR"}},"identifier":{"@type":"PropertyValue","name":"American Cancer Society","value":"3d8fe5c2-8174-43e7-8f9f-efe06f2ef94a"}}Full-Time
Confirmed live in the last 24 hours
Advocacy, research, and patient support for cancer
$44k/yr
Mid, Senior
Salt Lake City, UT, USA
Get referrals →
You have ways to get a American Cancer Society referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 13 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
The American Cancer Society works to combat cancer and improve the lives of those affected by it. They focus on advocacy, research, and providing support to patients and their families. Their efforts include promoting cancer prevention, early detection, and effective treatment options. What sets the American Cancer Society apart from other organizations is their comprehensive approach that combines research funding with direct support for patients, ensuring that individuals have access to the resources they need throughout their cancer journey. The ultimate goal of the American Cancer Society is to end cancer for everyone, making sure that no one faces cancer alone.
Company Size
5,001-10,000
Company Stage
Series B
Total Funding
$2.7M
Headquarters
Atlanta, Georgia
Founded
2000
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Paid Vacation
401(k) Retirement Plan
Wellness Program
Professional Development Budget
Recommendation based on AMPLIFY Phase III trial which showed Calquencecombinations demonstrated statistically significant and clinically meaningfulimprovement in progression-free survival vs. chemoimmunotherapyA fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the AMPLIFY Phase III trial, which were presented at the American Society of Haematology (ASH) 2024 Annual Meeting and published in The New England Journal of Medicine.1Results showed Calquence plus venetoclax reduced the risk of disease progression or death by 35% compared to standard-of-care chemoimmunotherapy (investigator’s choice of fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab; hazard ratio [HR] 0.65; 95% confidence interval [CI] 0.49-0.87; p=0.0038). Calquence plus venetoclax with obinutuzumab demonstrated a 58% reduction in the risk of disease progression or death compared to standard-of-care chemoimmunotherapy (HR 0.42; 95% CI 0.30-0.59; p<0.0001).2At three years, 77% of patients treated with Calquence plus venetoclax and 83% of patients treated with Calquence plus venetoclax and obinutuzumab were progression free, versus 67% of patients treated with chemoimmunotherapy.1 Median progression-free survival (PFS) was not reached for either experimental arm versus 47.6 months for chemoimmunotherapy.1Wojciech Jurczak, MD, Maria Sklodowska-Curie National Institute of Oncology, Kraków, Poland and investigator for the trial, said: “Chronic lymphocytic leukaemia is an incurable cancer which means patients live with the disease and stay on treatment for many years, which can have long-term effects. The fixed-duration Calquence regimens will allow patients to take breaks from their treatment, reducing the risk of long-term adverse events and drug resistance.”Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “With this recommendation, Calquence plus venetoclax can potentially be the only all-oral second-generation BTK inhibitor option approved in Europe for patients with previously untreated chronic lymphocytic leukaemia. Calquence has demonstrated efficacy and safety in fixed-duration and treat-to-progression regimens providing patients and their doctors more treatment flexibility.”CLL is the most common type of leukaemia in adults, with an estimated 27,000 patients diagnosed in the UK, France, Germany, Spain and Italy in 2024.3The safety and tolerability of Calquence was consistent with its known safety profile, and no new safety signals were identified.Regulatory applications for Calquence plus venetoclax, with or without obinutuzumab, in this setting are currently under review in several countries based on the AMPLIFY results.NotesChronic lymphocytic leukaemia (CLL)CLL is the most prevalent type of leukaemia in adults, with over 117,000 new cases globally in 2021.4 Although some people with CLL may not experience any symptoms at diagnosis, others may experience symptoms, such as weakness, fatigue, weight loss, chills, fever, night sweats, swollen lymph nodes and abdominal pain.5 In CLL, there is an accumulation of abnormal lymphocytes within the blood, bone marrow and lymph nodes. As the number of abnormal cells increases, there is less room within the marrow for the production of normal white blood cells, red blood cells and platelets.6 This could result in infection, anaemia and bleeding
OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management of the disease, improved risk stratification and therefore the ability of the BLC procedure to help urologists and patients make well-informed decisions. The American Urological Association Annual Congress 2025 was held April 26-28, at the Venetian Convention & Expo Center in Las Vegas, NV, USA.Three abstracts were presented from Photocure's U.S. Blue Light Cystoscopy with Cysview Registry, a large multicenter bladder cancer patient registry of real-world data, established by Photocure in 2014 and projected to enroll 4,400 patients. In addition, the study protocol of a randomized controlled non-inferiority trial comparing a multidisciplinary approach including PDD-guided primary TURBT to reduce the patients' burden of second resection including a total of 327 patients has been presented. This investigator-initiated trial is supported by Photocure.The abstract sessions on Saturday, April 26:"Upstaging and Risk Migration with BLC for NMIBC: Results from a prospective multicenter registry" by Alireza Ghoreifi, Duke UniversityThe study looked at 2,854 NMIBC* patients from the US Blue Light Cystoscopy with Cysview Registry. A total of 201 (7%) patients had at least one malignant lesion detected exclusively by BLC while having a negative WLC
Fixed-duration Calquence recommended in EU for CLL
Tampa, FL - April 28, 2025 - The American Cancer Society (ACS) has announced an innovative partnership with Besitos, a leading gaming company, to merge entertainment with philanthropy.
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025